Executive Summary
Key Points
- 20–30% of AL amyloidosis presents with cardiac-predominant disease without clinically significant nephrotic syndrome
- Lambda light chains encoded by Vλ1 and Vλ6 germline gene segments have inherent cardiotrophic properties — they preferentially target myocardium over kidney
- The absence of nephrotic syndrome removes the most recognizable "trigger" for amyloid evaluation, contributing to diagnostic delays averaging 13 months
- Cardiac ascites (high SAAG + high fluid protein) mimics cirrhosis on imaging but reflects intact hepatic sinusoidal fenestrations under elevated RA pressure
- Proteinuria phenotyping (ACR vs PCR, albumin fraction) reveals overflow light chain proteinuria even when total protein is sub-nephrotic
- FLC interpretation in CKD requires renal-adjusted ratios — a lambda-predominant ratio below the renal-adjusted lower limit signals clonal disease regardless of absolute levels
1. Cardiac-Predominant AL: An Underrecognized Phenotype
The clinical teaching "AL amyloidosis = nephrotic syndrome" is incorrect and dangerous. While renal involvement with nephrotic-range proteinuria is a common presentation (~60–70% of AL patients), a substantial minority — estimated at 20–30% — present with cardiac-predominant disease where the kidney is either uninvolved or shows only sub-nephrotic proteinuria.
1.1 Why Lambda Targets the Heart
The organ tropism of AL amyloidosis is determined by the specific germline gene segment encoding the variable region of the amyloidogenic light chain:
| Germline Gene | Primary Organ Target | Frequency in AL |
|---|---|---|
| Vλ6 (IGLV6-57) | Kidney (mesangial, GBM) | Most common in renal AL |
| Vλ1 (IGLV1-44) | Heart | Overrepresented in cardiac AL |
| Vλ3 (IGLV3-1) | Heart, soft tissue | Common overall |
| Vκ1 (IGKV1-33) | Liver, kidney | Most common kappa in AL |
| Vκ4 | Kidney (LCDD pattern) | Overrepresented in LCDD |
Lambda light chains — particularly Vλ1 — have amino acid sequences that promote direct cardiomyocyte toxicity through p38 MAPK activation and oxidative stress before fibrils form. This means the heart is being damaged by soluble prefibrillar intermediates even before tissue biopsy would show Congo red-positive deposits. The kidney may be relatively spared because the same light chain variable region lacks the structural features that promote mesangial deposition.
Warning
The revised mental model for nephrologists: "AL amyloidosis can cause catastrophic cardiac disease — including cardiogenic shock-range hemodynamics — with an M-protein so small it barely registers on immunofixation and proteinuria that is sub-nephrotic or absent." Organ dysfunction severity in AL does not correlate with clone size; the intrinsic amyloidogenicity of the light chain variable domain determines tissue injury.
2. Why Absence of Nephrotic Syndrome Delays Diagnosis
The diagnostic cascade for AL amyloidosis is typically triggered by one of three findings: nephrotic syndrome, unexplained cardiomyopathy, or neuropathy. When the kidney is not prominently involved:
| Typical Trigger | Who Orders the Workup | In Cardiac-Predominant AL |
|---|---|---|
| Nephrotic syndrome | Nephrologist orders SPEP, FLC, kidney biopsy | Absent or sub-nephrotic — trigger never fires |
| Unexplained LVH / HFpEF | Cardiologist may not screen for amyloid | Attributed to hypertension, aging, or "HFpEF" |
| Neuropathy | Neurologist orders FLC, immunofixation | Variable; may or may not be present |
The result: cardiac-predominant AL is misdiagnosed as generic HFpEF, hypertensive heart disease, or "diastolic dysfunction" for a median of 13 months. Each month of delay allows progressive cardiac amyloid deposition and advancement from Stage I/II to Stage III/IIIb, with survival implications measured in years lost.
Clinical Pearl
The three pillars of improving AL amyloidosis outcomes are: (1) Early recognition before advanced organ damage, (2) rapid and deep hematologic response, and (3) comprehensive multi-specialty supportive care. Diagnostic delay undermines the first pillar and limits the effectiveness of the other two. In cardiac-predominant AL, the nephrologist may never see the patient — making cardiologist awareness the critical bottleneck.
3. Proteinuria Phenotyping: Finding Clues in Sub-Nephrotic Disease
Even when total proteinuria is sub-nephrotic, ordering both ACR and PCR simultaneously reveals diagnostic information:
| Albumin Fraction (ACR/PCR) | Pattern | Typical Diagnoses |
|---|---|---|
| >80% | Pure glomerular | Diabetic nephropathy, FSGS, membranous, MCD |
| 60–80% | Mixed | Glomerular disease + AKI, early overflow |
| <60% | Significant non-albumin component | Free light chain excretion, tubular proteinuria |
| <30% | Predominantly non-albumin | Overflow proteinuria (light chains), isolated tubular disease |
In cardiac-predominant AL, the patient may have a PCR of 1.5 g/g with ACR of 0.4 g/g (albumin fraction 27%). The non-albumin fraction of 1.1 g/g — in the absence of cast nephropathy — strongly suggests free light chain excretion. This single, inexpensive maneuver can be the clue that triggers the correct workup.
Clinical Pearl
Ordering both ACR and PCR simultaneously is the cheapest screening maneuver for detecting light chain involvement of the kidney. When the PCR substantially exceeds the ACR, non-albumin protein is present — and the most common cause of large-volume non-albumin proteinuria is free light chain excretion. The dipstick, which detects primarily albumin, will underestimate total proteinuria when light chains are present.
4. Cardiac Ascites vs. Hepatic Ascites: The SAAG Framework
Advanced cardiac amyloidosis with severe right heart failure can present with massive ascites as the dominant clinical problem. Congestive hepatopathy from elevated RA pressure can mimic cirrhosis on CT imaging (nodular liver, hepatomegaly, splenomegaly), leading to diagnostic misdirection.
4.1 Ascitic Fluid Analysis
| Parameter | Cardiac Ascites | Cirrhotic Ascites |
|---|---|---|
| SAAG | ≥1.1 g/dL (portal HTN present) | ≥1.1 g/dL (portal HTN present) |
| Ascitic fluid protein | ≥2.5 g/dL | <2.5 g/dL |
| Mechanism | Intact sinusoidal fenestrations under high pressure — protein-rich transudation | Capillarized sinusoids — protein-poor filtrate |
| Serum albumin | Often preserved (≥3.5 g/dL) | Low (hypoalbuminemia) |
The Diagnostic Key
High SAAG (≥1.1) + High fluid protein (≥2.5 g/dL) = Cardiac etiology until proven otherwise. In cirrhosis, capillarization of sinusoidal endothelium prevents protein passage, producing low-protein ascites. In cardiac congestion, intact fenestrations allow protein-rich fluid to pass into the peritoneal cavity. A patient with massive ascites and preserved serum albumin (≥3.5 g/dL) is unlikely to have primary cirrhosis as the etiology.
Warning: INR in Anticoagulated Patients
In patients receiving warfarin, the INR is entirely uninterpretable as a marker of hepatic synthetic function. An INR of 4.0 on warfarin reflects pharmacologic anticoagulation, not hepatic failure. A clinician calculating a high MELD score from this INR would conclude severe hepatic decompensation when the liver may be functionally intact. Use albumin and Factor V level instead.
5. FLC Interpretation in CKD: The Cardiac-Predominant Challenge
Cardiac-predominant AL patients may have concurrent CKD from cardiorenal syndrome (reduced perfusion, elevated venous pressure) rather than primary renal amyloid. This creates the FLC interpretation challenge: elevated FLC from CKD retention obscuring the clonal signal.
5.1 The Renal-Adjusted Ratio as Diagnostic Anchor
The practical rule validated by the iStopMM study:
- Is the ratio abnormal for this patient’s GFR? Use iStopMM eGFR-adjusted intervals. A ratio that falls outside the renal-adjusted interval signals clonal disease regardless of absolute levels.
- What direction is the ratio?
- Very low ratio (lambda excess, <0.2) + cardiac dysfunction → AL lambda amyloidosis until proven otherwise
- Very high ratio (kappa excess, >5) + cardiac dysfunction → Kappa AL or kappa LCDD
- Is the uninvolved chain suppressed? CKD elevates both chains proportionally. A suppressed uninvolved chain (below normal range despite CKD) is the signature of clonal suppression, not renal physiology.
Warning: dFLC in Nephrotic Proteinuria
In patients with heavy nephrotic-range proteinuria, serum FLC levels are spuriously lowered by urinary losses. The degree of clonal disease burden is likely greater than the serum FLC values imply. Do not use the dFLC alone to assess clone burden in this setting — the measured dFLC is a floor, not a ceiling.
6. Cardiac Biomarker Staging in AL Amyloidosis
6.1 Mayo 2004 Staging
| Stage | Criteria | Median OS |
|---|---|---|
| I | TnT <0.035 ng/mL AND NT-proBNP <332 pg/mL | ~26 months |
| II | Either elevated | ~11 months |
| III | Both elevated | ~4 months |
6.2 Mayo 2012 Revised Staging (Adding dFLC)
| Stage | Criteria | Median OS |
|---|---|---|
| I | 0 risk factors (NT-proBNP <1800, TnT <0.025, dFLC <18 mg/dL) | ~95 months |
| II | 1 risk factor | ~60 months |
| III | 2 risk factors | ~16 months |
| IV | 3 risk factors | ~6 months |
The European modification subdivides Stage III into IIIa (NT-proBNP <8,500) and IIIb (≥8,500), with IIIb carrying median survival of ~5 months. Stage IIIb patients were excluded from the ANDROMEDA trial establishing Dara-VCd.
Clinical Pearl
Natriuretic peptides (BNP, NT-proBNP) are renally cleared. In CKD, NT-proBNP rises from reduced clearance — not necessarily cardiac disease. However, a BNP >4,000 pg/mL far exceeds what CKD alone produces. Published data suggest CKD Stage III+ shifts the BNP threshold for cardiac amyloid involvement to ~427 pg/mL — still orders of magnitude below values seen in advanced cardiac AL.
7. Treatment Considerations
7.1 Standard of Care: Dara-VCd (ANDROMEDA)
Daratumumab, bortezomib, cyclophosphamide, and dexamethasone achieved a hematologic complete response rate of 53.3% vs 18.1% for VCd alone in newly diagnosed AL amyloidosis (ANDROMEDA, NEJM 2021). However, key eligibility nuances for cardiac-predominant patients:
- Stage IIIb patients (NT-proBNP ≥8,500) were excluded
- eGFR ≥20 mL/min was required — cardiorenal patients may be borderline
- Dexamethasone carries hemodynamic and glycemic risk in vasopressor-dependent patients
7.2 Supportive Care Principles
- Diuresis: Guided by RHC hemodynamics; avoid aggressive preload reduction
- Avoid: ACE inhibitors, ARBs, beta-blockers, non-DHP CCBs, digoxin
- Screen for Factor X deficiency before any invasive procedure — AL amyloid fibrils adsorb Factor X in up to 14% of patients
- Goals of care: Discuss prognosis honestly and early; goals-of-care conversations should occur in parallel with diagnostic workup, not after
Warning: Factor X Deficiency
Systemic AL amyloid fibrils adsorb and sequester clotting Factor X, producing an acquired Factor X deficiency in up to 14% of AL amyloidosis patients. This causes procedure-related hemorrhage risk independent of platelet count and INR. A Factor X activity level should be sent before kidney biopsy, bone marrow biopsy, or RHC.
8. Integrating the Amyloid Series: A Clinical Framework
The five modules of this series converge on a unified clinical framework for the nephrologist encountering amyloidosis:
| Clinical Finding | What It Means | Module Reference |
|---|---|---|
| HFpEF with thick walls in elderly male | Screen for ATTR-CM and AL | Module 1: ATTR |
| Abnormal FLC ratio in CKD patient | Apply renal-adjusted intervals; investigate if outside range | Module 2: Monoclonal Protein |
| Preserved EF with diuretic resistance | Calculate SVI; consider RHC for hemodynamic assessment | Module 3: Misleading Echo |
| Elevated RA, low CI on RHC | Restrictive physiology; define safe filling pressure range | Module 4: RHC |
| Cardiac failure without nephrotic syndrome | Cardiac-predominant AL; lambda germline targeting myocardium | Module 5 (this page) |
References
- Merlini G, Dispenzieri A, Sanchorawala V, et al. Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Primers. 2018;4(1):38. PubMed
- Gertz MA. Immunoglobulin light chain amyloidosis: 2024 update. Am J Hematol. 2024;99(2):309-324. PubMed
- Kastritis E, Palladini G, Minnema MC, et al. Daratumumab-based treatment for AL amyloidosis. N Engl J Med. 2021;385(1):46-58. PubMed
- Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and NT-proBNP: staging system for primary systemic amyloidosis. J Clin Oncol. 2004;22(18):3751-3757. PubMed
- Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for AL amyloidosis. J Clin Oncol. 2012;30(9):989-995. PubMed
- Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349(6):583-596. PubMed
- Palladini G, Hegenbart U, Milani P, et al. Renal staging in AL amyloidosis. Blood. 2014;124(15):2325-2332. PubMed
- Lilleness B, Ruberg FL, Mussinelli R, et al. BNP-based survival staging in AL amyloidosis. Blood. 2019;133(3):215-223. PubMed
- Thorsteinsdottir S, Gislason GK, Aspelund T, et al. iStopMM FLC reference intervals in CKD. Blood Cancer J. 2022;12(9):133. PubMed
- Runyon BA; AASLD. Management of adult patients with ascites due to cirrhosis. Hepatology. 2013;57(4):1651-1653. PubMed
- Kittleson MM, Maurer MS, Ambardekar AV, et al. Cardiac amyloidosis: AHA scientific statement. Circulation. 2020;142(1):e7-e22. PubMed
- Leung N, Bridoux F, Batuman V, et al. Evaluation of MGRS: IKGMG consensus report. Nat Rev Nephrol. 2019;15(1):45-59. PubMed
Amyloid Series Navigation
© Urine Nephrology Now | Amyloid Series
Andrew Bland, MD, MBA, MS